[Analysis of drug therapy of lung cancer in Hungary].

Magyar onkologia (2013-04-11)
Judit Moldvay, György Rokszin, Zsolt Abonyi-Tóth, Lajos Katona, Gábor Kovács
RESUMO

Hungary is a world leader in lung cancer deaths, so it is particularly important that patients could have access to modern treatments. The aim of our analysis was to find how drug treatments are used in Hungary and how they are compatible with international practice. The in-patient and prescription database of the National Health Insurance Fund for three years (2008-2010) was used to study the frequency of certain chemotherapy protocols, the duration of therapies, and the changes in the individual protocols and drugs used for lung cancer treatment (ICD: C33H0-C34) during the reviewed period. We did not differentiate between neoadjuvant and adjuvant treatment and therapy after progression. During the study period 12326 lung cancer patients received first-line chemotherapy, one third of those (n=3791) received second-line, and one third of those (n=1174) third-line treatment. The average treatment duration was between 3 and 4 months. The first-line treatment of NSCLC mainly consisted of platinum treatment in combination with third generation cytotoxic agents. A downward trend of gemcitabine, still the most common combination compound, was observed, in parallel with the increased use of paclitaxel, and as a consequence carboplatin replaced cisplatin. Among new agents the use of pemetrexed and bevacizumab has increased. Pemetrexed appeared mainly in second-line treatment, while erlotinib also in second, but mostly in third line. The first-line treatment of SCLC consisted of a platinum-etoposide combination, and in second-line setting topotecan was the most commonly used drug. According to our results the chemotherapeutic combinations and sequencing are in accordance with international and national recommendations. Further detailed analysis of the available data may help to obtain more accurate picture of the efficacy of lung cancer treatments as well.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Etoposide, synthetic, 98.0-105.0%, powder
Sigma-Aldrich
Guanine, 98%
Supelco
Guanine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Topotecan hydrochloride hydrate, ≥98% (HPLC and enzymatic)
Sigma-Aldrich
Guanine, BioUltra